-
-
-
-
-
-
-
Goldman Sachs Reiterates Buy Rating on Madrigal Pharmaceuticals (MDGL)
-
-
-
-
-
-
-
Madrigal Pharmaceuticals (MDGL) PT Raised to $640 at Truist Securities, 'We remain buyers'
-
-
-
-
-
-
-
BofA Securities Upgrades Madrigal Pharmaceuticals (MDGL) to Neutral
-
-
-
-
-
-
-
H.C. Wainwright Starts Madrigal Pharmaceuticals (MDGL) at Buy
-
-
-
-
-
-
-
Piper Sandler Reiterates Overweight Rating on Madrigal Pharmaceuticals (MDGL)
-
-
-
-
-
-
-
Madrigal receives patent allowance for Rezdiffra through 2044
-
-
-
-
-
-
-
Cantor Fitzgerald Reiterates Neutral Rating on Madrigal Pharmaceuticals (MDGL)
-
353,174 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

